2024
681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data
Vleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of malignancyModerate-to-severe diseaseCohort entry dateAtopic dermatitisRheumatoid arthritisFollow-upModerate-to-severe atopic dermatitisSkin cancerNon-AD cohortIncidence of malignancyNonmelanoma skin cancerSubgroup of patientsNon-AD controlsFollow-up periodCox proportional hazards modelsChronic liver diseaseEffect of disease activityInternational Classification of Diseases (ICD)-9Population-based studyProportional hazards modelClinformatics Data MartSystemic therapyClaims-based studyOptum Clinformatics Data Mart697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data
Lebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.Peer-Reviewed Original ResearchNon-melanoma skin cancerRisk of non-melanoma skin cancerModerate-to-severe diseaseAtopic dermatitisNon-AD cohortRheumatoid arthritisControl cohortNon-melanoma skin cancer riskModerate-to-severe atopic dermatitisNon-melanoma skin cancer incidenceMultivariate Cox proportional hazards modelSkin cancerModerate-to-severe ADCohort entry dateSquamous cell carcinomaMatched control cohortIntermittent sun exposureFollow-up timeNon-AD controlsRetrospective observational studyCox proportional hazards modelsEffect of disease activityPopulation-based studyProportional hazards modelClinformatics Data Mart533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure
Bunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar M, Irvine A, Levy G, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg J. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. British Journal Of Dermatology 2024, 190: ii35-ii36. DOI: 10.1093/bjd/ljad498.037.Peer-Reviewed Original ResearchNon-melanoma skin cancerMajor adverse cardiovascular eventsVenous thromboembolic eventsAtopic dermatitisAdverse eventsAdjudicated major adverse cardiovascular eventsOral Janus kinase 1Rate of serious infectionTreatment-emergent adverse eventsLong-term safety dataDuration of follow-upConcomitant topical corticosteroidsEfficacy of upadacitinibDouble-blind periodRate of adverse eventsPhase 3 studyDoses of upadacitinibEczematous skin lesionsExposure-adjusted ratesMATERIALS & METHODSYear of treatmentAdverse cardiovascular eventsBenefit-risk profileInflammatory skin diseaseLong-term safety
2022
JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
Daniele S, Bunick C. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies. Journal Of Drugs In Dermatology 2022, 21: 1298-1303. PMID: 36468956, DOI: 10.36849/jdd.7187.Peer-Reviewed Original ResearchConceptsIncidence of adverse eventsAdverse cardiac eventsNon-melanoma skin cancerSystemic therapyAdverse eventsAtopic dermatitisCardiac eventsJAK inhibitorsVenous thromboembolismControl patientsSkin cancerIncidence rateTreatment of atopic dermatitisSystemic immunosuppressive therapyRates of non-melanoma skin cancerTraditional systemic therapiesIncidence of malignancyLong-term clinical trial dataReference control populationAtopic dermatitis treatmentBaseline rateLow incidence rateClinical trial dataImmunosuppressive therapySystemic corticosteroids